Tixagevimab–cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study
The use of tixagevimab-cilgavimab as PrEP in vaccinated dialysis patients during the Omicron surge did not prevent breakthrough infections but significantly reduced COVID-19-related hospitalizations. Further research should prioritize alternative strategies.
Authors
- Jackrapong Bruminhent (ORCID: https://orcid.org/0000-0003-0930-8936)
- Sarinya Boongird (ORCID: https://orcid.org/0000-0002-3194-1511)
- Arkom Nongnuch (ORCID: https://orcid.org/0000-0003-3876-9432)
- Sethanant Sethakarun
- Chagriya Kitiyakara (ORCID: https://orcid.org/0000-0001-6340-3534)
- Suchai Sritippayawan (ORCID: https://orcid.org/0000-0002-2291-1580)
- Sasisopin Kiertiburanakul (ORCID: https://orcid.org/0000-0003-4379-4704)
- Thatsaphan Srithongkul (ORCID: https://orcid.org/0000-0002-5860-3395)
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
- Dusit Thani College (TH)
- Rajamangala Institute of kidney disease (TH)
- Ramathibodi Hospital (TH)
- Bangkok University (TH)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1093/ckj/sfae309
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- Mahidol University
- Faculty of Medicine Siriraj Hospital, Mahidol University